Synthesis of a cell penetrating peptide modified superparamagnetic iron oxide and MRI detection of bladder cancer

Chen Ding, Kaijie Wu, Weiyi Wang, Zhenfeng Guan, Lei Wang, Xinyang Wang, Rong Wang, Li Liu, Jinhai Fan

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Bladder cancer is the most common malignancy of the urinary tract for which the accurate measurement of minimal residual disease is critical to treatment and determining prognosis. Although cystoscope examination and voided urine cytology remain the current standard of care for detecting residual disease, these approaches are limited by mechanical trauma and lack sensitivity. To develop a new accurate noninvasive method, we developed a novel contrast agent where the surface of superparamagnetic iron oxide (SPIO) nanoparticles is functionalized with a bladder cancer-specific fluorescein isothiocyanate (FITC) labeled cell penetrating peptide (CPP)-polyarginine peptides (R11) for active targeting and imaging. The stable nanoparticles have an average hydrodynamic diameter of 51 nm, surface charge of -21 mV and MRI r2 relaxivity 135 mM-1s-1. In vitro cell studies demonstrated that the R11-conjugated SPIO (SPIO-R11) nanoparticles were taken up by bladder cancer cells (T24) in a dose-dependent manner, which was higher than unconjugated SPIO. TEM showed that SPIO-R11 was mainly concentrated on cell vesicle and lysosome, not in cell nucleus, and no obvious damage was seen on cell ultrastructure. Moreover, uptake of the nanoparticles showed significantly more SPIO-R11 accumulation in bladder cancer cells than in immortalized bladder epithelial cells unlike control SPIO. Further, SPIO-R11 was compatible with immortalized bladder epithelial cells at all tested concentrations up to 200 μg/mL after 72 h incubation. Moreover, SPIO-R11 decreased the magnetic resonance T2 relaxation time by 73% in tumors cells in vitro compared to 12% with SPIO. These results indicate great potential of SPIO-R11 as contrast agent to target bladder cancer for diagnostic and therapeutic applications.

Original languageEnglish (US)
Pages (from-to)4718-4729
Number of pages12
JournalOncotarget
Volume8
Issue number3
DOIs
StatePublished - 2017

Fingerprint

Cell-Penetrating Peptides
Urinary Bladder Neoplasms
Nanoparticles
Contrast Media
Urinary Bladder
ferric oxide
Cystoscopes
Epithelial Cells
Residual Neoplasm
Hydrodynamics
Standard of Care
Lysosomes
Fluorescein
Cell Nucleus
Urinary Tract
Cell Biology
Neoplasms
Magnetic Resonance Spectroscopy

Keywords

  • Bladder cancer
  • Cell penetrating peptide
  • Magnetic resonance imaging
  • Superparamagnetic iron oxide
  • Targeted diagnosis

ASJC Scopus subject areas

  • Oncology

Cite this

Synthesis of a cell penetrating peptide modified superparamagnetic iron oxide and MRI detection of bladder cancer. / Ding, Chen; Wu, Kaijie; Wang, Weiyi; Guan, Zhenfeng; Wang, Lei; Wang, Xinyang; Wang, Rong; Liu, Li; Fan, Jinhai.

In: Oncotarget, Vol. 8, No. 3, 2017, p. 4718-4729.

Research output: Contribution to journalArticle

Ding, Chen ; Wu, Kaijie ; Wang, Weiyi ; Guan, Zhenfeng ; Wang, Lei ; Wang, Xinyang ; Wang, Rong ; Liu, Li ; Fan, Jinhai. / Synthesis of a cell penetrating peptide modified superparamagnetic iron oxide and MRI detection of bladder cancer. In: Oncotarget. 2017 ; Vol. 8, No. 3. pp. 4718-4729.
@article{347b335292de447395fde26099729658,
title = "Synthesis of a cell penetrating peptide modified superparamagnetic iron oxide and MRI detection of bladder cancer",
abstract = "Bladder cancer is the most common malignancy of the urinary tract for which the accurate measurement of minimal residual disease is critical to treatment and determining prognosis. Although cystoscope examination and voided urine cytology remain the current standard of care for detecting residual disease, these approaches are limited by mechanical trauma and lack sensitivity. To develop a new accurate noninvasive method, we developed a novel contrast agent where the surface of superparamagnetic iron oxide (SPIO) nanoparticles is functionalized with a bladder cancer-specific fluorescein isothiocyanate (FITC) labeled cell penetrating peptide (CPP)-polyarginine peptides (R11) for active targeting and imaging. The stable nanoparticles have an average hydrodynamic diameter of 51 nm, surface charge of -21 mV and MRI r2 relaxivity 135 mM-1s-1. In vitro cell studies demonstrated that the R11-conjugated SPIO (SPIO-R11) nanoparticles were taken up by bladder cancer cells (T24) in a dose-dependent manner, which was higher than unconjugated SPIO. TEM showed that SPIO-R11 was mainly concentrated on cell vesicle and lysosome, not in cell nucleus, and no obvious damage was seen on cell ultrastructure. Moreover, uptake of the nanoparticles showed significantly more SPIO-R11 accumulation in bladder cancer cells than in immortalized bladder epithelial cells unlike control SPIO. Further, SPIO-R11 was compatible with immortalized bladder epithelial cells at all tested concentrations up to 200 μg/mL after 72 h incubation. Moreover, SPIO-R11 decreased the magnetic resonance T2 relaxation time by 73{\%} in tumors cells in vitro compared to 12{\%} with SPIO. These results indicate great potential of SPIO-R11 as contrast agent to target bladder cancer for diagnostic and therapeutic applications.",
keywords = "Bladder cancer, Cell penetrating peptide, Magnetic resonance imaging, Superparamagnetic iron oxide, Targeted diagnosis",
author = "Chen Ding and Kaijie Wu and Weiyi Wang and Zhenfeng Guan and Lei Wang and Xinyang Wang and Rong Wang and Li Liu and Jinhai Fan",
year = "2017",
doi = "10.18632/oncotarget.13578",
language = "English (US)",
volume = "8",
pages = "4718--4729",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "3",

}

TY - JOUR

T1 - Synthesis of a cell penetrating peptide modified superparamagnetic iron oxide and MRI detection of bladder cancer

AU - Ding, Chen

AU - Wu, Kaijie

AU - Wang, Weiyi

AU - Guan, Zhenfeng

AU - Wang, Lei

AU - Wang, Xinyang

AU - Wang, Rong

AU - Liu, Li

AU - Fan, Jinhai

PY - 2017

Y1 - 2017

N2 - Bladder cancer is the most common malignancy of the urinary tract for which the accurate measurement of minimal residual disease is critical to treatment and determining prognosis. Although cystoscope examination and voided urine cytology remain the current standard of care for detecting residual disease, these approaches are limited by mechanical trauma and lack sensitivity. To develop a new accurate noninvasive method, we developed a novel contrast agent where the surface of superparamagnetic iron oxide (SPIO) nanoparticles is functionalized with a bladder cancer-specific fluorescein isothiocyanate (FITC) labeled cell penetrating peptide (CPP)-polyarginine peptides (R11) for active targeting and imaging. The stable nanoparticles have an average hydrodynamic diameter of 51 nm, surface charge of -21 mV and MRI r2 relaxivity 135 mM-1s-1. In vitro cell studies demonstrated that the R11-conjugated SPIO (SPIO-R11) nanoparticles were taken up by bladder cancer cells (T24) in a dose-dependent manner, which was higher than unconjugated SPIO. TEM showed that SPIO-R11 was mainly concentrated on cell vesicle and lysosome, not in cell nucleus, and no obvious damage was seen on cell ultrastructure. Moreover, uptake of the nanoparticles showed significantly more SPIO-R11 accumulation in bladder cancer cells than in immortalized bladder epithelial cells unlike control SPIO. Further, SPIO-R11 was compatible with immortalized bladder epithelial cells at all tested concentrations up to 200 μg/mL after 72 h incubation. Moreover, SPIO-R11 decreased the magnetic resonance T2 relaxation time by 73% in tumors cells in vitro compared to 12% with SPIO. These results indicate great potential of SPIO-R11 as contrast agent to target bladder cancer for diagnostic and therapeutic applications.

AB - Bladder cancer is the most common malignancy of the urinary tract for which the accurate measurement of minimal residual disease is critical to treatment and determining prognosis. Although cystoscope examination and voided urine cytology remain the current standard of care for detecting residual disease, these approaches are limited by mechanical trauma and lack sensitivity. To develop a new accurate noninvasive method, we developed a novel contrast agent where the surface of superparamagnetic iron oxide (SPIO) nanoparticles is functionalized with a bladder cancer-specific fluorescein isothiocyanate (FITC) labeled cell penetrating peptide (CPP)-polyarginine peptides (R11) for active targeting and imaging. The stable nanoparticles have an average hydrodynamic diameter of 51 nm, surface charge of -21 mV and MRI r2 relaxivity 135 mM-1s-1. In vitro cell studies demonstrated that the R11-conjugated SPIO (SPIO-R11) nanoparticles were taken up by bladder cancer cells (T24) in a dose-dependent manner, which was higher than unconjugated SPIO. TEM showed that SPIO-R11 was mainly concentrated on cell vesicle and lysosome, not in cell nucleus, and no obvious damage was seen on cell ultrastructure. Moreover, uptake of the nanoparticles showed significantly more SPIO-R11 accumulation in bladder cancer cells than in immortalized bladder epithelial cells unlike control SPIO. Further, SPIO-R11 was compatible with immortalized bladder epithelial cells at all tested concentrations up to 200 μg/mL after 72 h incubation. Moreover, SPIO-R11 decreased the magnetic resonance T2 relaxation time by 73% in tumors cells in vitro compared to 12% with SPIO. These results indicate great potential of SPIO-R11 as contrast agent to target bladder cancer for diagnostic and therapeutic applications.

KW - Bladder cancer

KW - Cell penetrating peptide

KW - Magnetic resonance imaging

KW - Superparamagnetic iron oxide

KW - Targeted diagnosis

UR - http://www.scopus.com/inward/record.url?scp=85012012642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012012642&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.13578

DO - 10.18632/oncotarget.13578

M3 - Article

VL - 8

SP - 4718

EP - 4729

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 3

ER -